

## **Radiopharm receives \$1.9 M advance on FY24 R&D tax incentive**

Sydney, Australia – 21 February 2024 – Radiopharm Theranostics Limited (ASX:RAD), a developer of a world class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce it has received \$1,900,000 from Radium Capital under a funding facility secured against Radiopharm’s anticipated FY24 Research and Development Tax Incentive (RDTI).

The funds will support the clinical trial pipeline and otherwise for general working capital of the Company.

The funding agreement with Radium Capital provides Radiopharm with early access to a portion of the Company’s anticipated FY24 RDTI. The facility is secured against the anticipated FY24 RDTI to be received from the Australian Taxation Office, with interest charged at a commercial rate. Repayment is timed to follow the anticipated receipt of the Company’s FY24 RDTI, and is due by 31 December 2024. The facility can be repaid at any time without penalty prior to this date.

The Australian Government RDTI program provides companies engaging in eligible activities with a refundable tax offset of up to 43.5%.

### **About Radiopharm Theranostics**

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm has been listed on ASX (RAD) since November 2021. The company has a pipeline of six distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the world’s leading universities and institutes. The pipeline has been built based on the potential to be first-to-market or best-in-class. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumour cancers including breast, kidney and brain. Learn more at [Radiopharmtheranostics.com](https://radiopharmtheranostics.com).

**Authorised on behalf of the Radiopharm Theranostics board of directors by Executive Chairman Paul Hopper.**

#### **For more information:**

Riccardo Canevari  
CEO & Managing Director  
P: +1 862 309 0293  
E: [rc@radiopharmtheranostics.com](mailto:rc@radiopharmtheranostics.com)

Paul Hopper  
Executive Chairman  
P: +61 406 671 515  
E: [paulhopper@lifescienceportfolio.com](mailto:paulhopper@lifescienceportfolio.com)

Matt Wright  
NWR Communications  
P: +61 451 896 420  
E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

**ASX ANNOUNCEMENT**  
**21 FEBRUARY 2024**



**Follow Radiopharm Theranostics:**

Website – <https://radiopharmtheranostics.com/>

Twitter – <https://twitter.com/TeamRadiopharm>

Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>

InvestorHub – <https://investorhub.radiopharmtheranostics.com/>

